Dr Reddy’s Plan for Major Expansion in US Market

"Normally every year, based on our portfolio and R&D investments, we prepare for 10 to 15 launches. But this year (2018-19), it could be 15 plus," the company's CFO Saumen Chakraborty told analysts and journalists.

Dr Reddy’s Plan for Major Expansion in US Market

Sharing is caring!

Hyderabad based Dr Reddy’s Laboratories expects to launch over 15 products in the US market in 2018-19, according to the CFO of the company. According to Dr Reddy’s plan of action the company official also remains optimistic for a double-digit growth in the domestic market in the ongoing financial year.

“Normally every year, based on our portfolio and R&D investments, we prepare for 10 to 15 launches. But this year (2018-19), it could be 15 plus,” the company’s CFO Saumen Chakraborty told analysts and journalists.

The company, which launched three products in the US during March quarter of 2017-18, has over 100 abbreviated new drug applications (ANDAs) lined up for approval with the US Food and Drug Administration (USFDA).

“We have over 100 ANDAs pending, many of them first-to-file, many of them complex assets, both at the API level as well as the finished dosage level,” CEO GV Prasad said.

CATEGORIES
TAGS
Share This

COMMENTS

Wordpress (0)
Disqus (0 )
shares
%d bloggers like this: